Bellicum Pharmacueticals Inc. (NASDAQ:BLCM) shares shot up 8.7% during trading on Friday . The company traded as high as $17.93 and last traded at $17.57, with a volume of 231,683 shares changing hands. The stock had previously closed at $16.17.

A number of research firms recently commented on BLCM. Piper Jaffray Cos. reaffirmed a “buy” rating on shares of Bellicum Pharmacueticals in a research report on Saturday, July 9th. Zacks Investment Research raised shares of Bellicum Pharmacueticals from a “sell” rating to a “hold” rating in a research report on Monday, July 11th. Finally, SunTrust Banks Inc. began coverage on shares of Bellicum Pharmacueticals in a research report on Thursday, June 2nd. They issued a “buy” rating and a $20.00 target price on the stock. Two analysts have rated the stock with a hold rating and four have given a buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $27.50.

The stock has a 50-day moving average of $14.09 and a 200 day moving average of $11.35. The firm’s market cap is $468.44 million.

Bellicum Pharmacueticals (NASDAQ:BLCM) last announced its quarterly earnings results on Monday, May 9th. The biopharmaceutical company reported ($0.44) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.51) by $0.07. On average, analysts anticipate that Bellicum Pharmacueticals Inc. will post ($2.22) earnings per share for the current fiscal year.

In other news, CTO Kevin M. Slawin sold 2,719 shares of the business’s stock in a transaction on Monday, July 18th. The shares were sold at an average price of $13.99, for a total transaction of $38,038.81. Following the transaction, the chief technology officer now directly owns 134,206 shares of the company’s stock, valued at $1,877,541.94. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider David M. Spencer sold 10,000 shares of the business’s stock in a transaction on Wednesday, July 27th. The stock was sold at an average price of $15.00, for a total transaction of $150,000.00. The disclosure for this sale can be found here.

An institutional investor recently raised its position in Bellicum Pharmacueticals stock. Morgan Stanley boosted its position in Bellicum Pharmacueticals Inc. (NASDAQ:BLCM) by 21.1% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 426,861 shares of the biopharmaceutical company’s stock after buying an additional 74,454 shares during the period. Morgan Stanley owned about 1.61% of Bellicum Pharmacueticals worth $8,653,000 at the end of the most recent reporting period.

Bellicum Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company uses its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.